# Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

> **NCT00542451** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 406 (actual)

## Conditions studied

- Breast Cancer
- Carcinoma of the Breast

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT00542451
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2014-04-21
- **Final completion:** 2022-08-30
- **Target enrollment:** 406 (ACTUAL)
- **Last updated:** 2024-06-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00542451

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00542451, "Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00542451. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*